WallStSmart

AMN Healthcare Services Inc (AMN)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1838% more annual revenue ($66.57B vs $3.43B). MRK leads profitability with a 4.8% profit margin vs 3.1%. AMN appears more attractively valued with a PEG of 1.71. AMN earns a higher WallStSmart Score of 62/100 (C+).

AMN

Buy

62

out of 100

Grade: C+

Growth: 5.3Profit: 4.0Value: 7.3Quality: 5.5
Piotroski: 4/9Altman Z: 2.27

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMNUndervalued (+59.9%)

Margin of Safety

+59.9%

Fair Value

$48.77

Current Price

$33.34

$15.43 discount

UndervaluedFair: $48.77Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$144.85

$62.01 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMN3 strengths · Avg: 8.7/10
EPS GrowthGrowth
321.3%10/10

Earnings expanding 321.3% YoY

P/E RatioValuation
12.4x8/10

Attractively priced relative to earnings

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

AMN4 concerns · Avg: 3.5/10
PEG RatioValuation
1.714/10

Expensive relative to growth rate

Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Market CapQuality
$1.29B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
3.1%3/10

3.1% margin — thin

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : AMN

The strongest argument for AMN centers on EPS Growth, P/E Ratio, Price/Book.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : AMN

The primary concerns for AMN are PEG Ratio, Revenue Growth, Market Cap. Thin 3.1% margins leave little buffer for downturns.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

AMN carries more volatility with a beta of 0.39 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AMN scores higher overall (62/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AMN Healthcare Services Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

AMN Healthcare Services, Inc. provides healthcare personnel solutions and staffing services to hospitals and healthcare facilities in the United States. The company is headquartered in Dallas, Taxas.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?